KRAS mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal setting
| Autor: | Lorenza Greco, Antonio Russo, Caterina De Luca, Roberta Sgariglia, Giancarlo Troncone, Ilaria Migliatico, Valerio Gristina, Pasquale Pisapia, Eduardo Clery, Umberto Malapelle, Claudio Bellevicine, Mariantonia Nacchio, Elena Vigliar, Francesco Pepe |
|---|---|
| Přispěvatelé: | Nacchio, M., Sgariglia, R., Gristina, V., Pisapia, P., Pepe, F., de Luca, C., Migliatico, I., Clery, E., Greco, L., Vigliar, E., Bellevicine, C., Russo, A., Troncone, G., Malapelle, U., Nacchio M., Sgariglia R., Gristina V., Pisapia P., Pepe F., de Luca C., Migliatico I., Clery E., Greco L., Vigliar E., Bellevicine C., Russo A., Troncone G., Malapelle U. |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Pulmonary and Respiratory Medicine AMG510 Settore MED/06 - Oncologia Medica Viral Oncogene medicine.disease_cause 03 medical and health sciences Basal (phylogenetics) 0302 clinical medicine G12C Medicine Epidermal growth factor receptor Liquid biopsy Lung cancer neoplasms Mutation biology business.industry Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Review Article on Improving Outcomes in Lung Cancer Through Early Diagnosis and Smoking Cessation medicine.disease Basal setting 030104 developmental biology Next generation sequencing (NGS) 030220 oncology & carcinogenesis Cancer research biology.protein Biomarker (medicine) KRAS business |
| Zdroj: | J Thorac Dis |
| Popis: | In advanced stage non-small cell lung cancer (NSCLC) patients, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) testing may soon acquire a predictive significance to select patients for AMG510 treatment. Since tissue samples are not always available, liquid biopsy may represent a viable option for KRAS testing. Here, we review the last three years clinical practice performed on 194 plasma based liquid biopsies by next generation sequencing (NGS) SiRe(®) panel. In particular, 36 (18.6%) KRAS mutated cases were identified, with an overall median allelic frequency of 5.0% (ranging between 0.2% and 46.8%). No concomitant mutations were observed in the other NSCLC clinical relevant genes included in the SiRe(®) panel, such as epidermal growth factor receptor (EGFR) and v-Raf murine sarcoma viral oncogene homolog B (BRAF). Exon 2 p.G12C was the most common detected mutation (13/36, 36.1%). In conclusion, our data update and confirm that SiRe(®) NGS panel represents a robust analytical tool to assess KRAS mutational status on circulating tumor DNA. Further investigation is required to design more cost-effective diagnostic algorithms to harmonize clinical relevant biomarker testing on tissue and blood in advanced stage NSCLC clinical practice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|